Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells

Fig. 4

MLN8237 treatment resulted in abnormal activation of Akt/Stat3 pathway. IMR32 cells were treated with 2 μmol/l of MLN8237. DMSO or no treatment as control. Cell samples were collected at 6 h and 24 h. Total proteins were extracted for western blot analysis for a Akt, pAkt, and mTOR; b GSK3β and pGSK3β; c Stat3 and pStat3. Gray values were calculated by imageJ software. The data were shown as the mean ± SEM of three independent experiments. *P < 0.05

Back to article page